查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1855054

前临床成像的全球市场:各类型，各产品，各用途，各终端用户，各流通管道，各地区 - 市场规模，产业趋势，机会分析，预测(2025年～2033年)

Global Preclinical Imaging Market: By Type, Product, Application, End-User, Distribution Channel and By Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 232 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

临床前影像市场经历了强劲且持续的成长，2024 年市场规模约为 20.406 亿美元。预计这一成长趋势将持续，到 2033 年市场规模将达到约 33.322 亿美元，2024 年至 2032 年的复合年增长率 (CAGR) 为 5.6%。这一增长反映了临床前成像在药物研发和生物医学研究中日益增长的重要性。

推动这成长的因素很多。其中一个关键因素是，随着製药和生技公司寻求加速新疗法的发现和审批，药物研发的投资不断增加。同时，对创新疗法以满足未被满足的医疗需求的需求也在不断增长，这进一步推动了对先进临床前影像工具的需求。另一个关键因素是对非侵入性成像技术的日益重视。这些方法有助于减少对动物模型的依赖，最大限度地减少伦理问题，并降低研究成本。

市场动态

临床前影像市场竞争激烈，成长强劲，这主要得益于药物研发和生物医学研究投资的不断增加。布鲁克、西门子医疗和珀金埃尔默等领先企业处于技术创新的前沿，它们利用战略合作伙伴关係并整合人工智慧 (AI) 来推动成像技术的发展。这些领导者不断开发涵盖各种成像模式（包括 MRI、PET、CT 和光学成像）的复杂系统，以满足研究人员不断变化的需求。此类技术创新的一个显着例子是 Levity 公司于 2025 年 9 月推出的 Living Image™ Synergy AI，这是一款专为体内成像研究人员设计的多模态分析软体。

在临床前影像市场，亚太地区已成为研发活动的关键中心，全球扩张仍是其重要的策略重点。 2024年，八家大型国际製药公司在北京设立了新的研发机构，凸显了该地区的重要性。在现有公司不断扩大业务的同时，新的市场参与者也在涌现。例如，临床前影像合约研究组织 (CRO) VeriSix 于2024年在巴黎推出了两个早期研究平台。

主要成长驱动因素

对临床前影像的持续需求正在推动研发管线的显着扩张，从而创造了创纪录的研究量。这一增长反映了对先进影像技术的日益依赖，以支持创新疗法的开发。例如，到 2024 年，专注于复杂细胞和基因疗法且需要体内追踪的活跃临床前计画数量将超过 800 个。这些计画凸显了影像技术在监测前沿疗法的体内行为和疗效方面发挥的关键作用。

新兴机会趋势

随着清除增强萤光断层扫描 (CFT) 的应用，临床前影像领域正在涌现一个强大的新前沿。这项创新成像技术独特地弥合了整体动物光学成像和高解析度体外显微镜之间的差距，使研究人员能够以前所未有的细节观察生物过程。到 2024 年，至少有五家大型製药公司已将 CFT 平台纳入其药物研发流程，尤其是在增强复杂生物製剂的生物分布研究方面。 CFT 能够以高达 4 微米的分辨率精确定位讯号，其成像能力比传统光学方法精细几个数量级。

优化障碍

不同研究机构和研究缺乏标准化的影像方案，这是阻碍临床前影像市场成长的一大挑战。影像技术、仪器设定和资料解读方法的差异导致研究结果不一致，使得不同实验室的结果难以比较和重现。这种不一致会削弱临床前影像资料的可靠性和可信度，而这对于推进药物研发和科学发现至关重要。

目录

第1章 调查架构

  • 调查目的
  • 产品概要
  • 市场区隔

第2章 调查手法

  • 定性调查
    • 一次资讯·二次资讯
  • 定量调查
    • 一级资讯来源和二级资讯来源
  • 初步调查受访者的各地区明细
  • 调查的前提
  • 市场规模·估计
  • 资料三角测量

第3章 摘要整理:前临床成像的全球市场

第4章 前临床成像的全球市场概要

  • 产业价值链分析
    • 原料供应商
    • 厂商
    • 经销商
    • 终端用户
  • 产业的展望
  • 大环境分析
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商业者的威胁
    • 竞争的程度
  • 市场动态和趋势
    • 成长促进因素
    • 阻碍因素
    • 机会
    • 主要趋势
  • COVID-19对市场成长趋势的影响评估
  • 市场成长与展望
    • 市场收益估计·预测, 2020-2033年
  • 竞争仪表板
    • 市场集中率
    • 企业占有率分析(金额%)、2024年
    • 竞争製图

第5章 前临床成像的全球市场:各类型

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • 产品
    • 成像服务

第6章 前临床成像的全球市场:各产品

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • CT成像
    • 光学成像
    • 超音波成像
    • MRI成像
    • PET/SPECT成像
    • 其他

第7章 前临床成像的全球市场，各用途

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • 研究开发
    • 药物研发

第8章 前临床成像的全球市场:各终端用户

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • 生物科技企业
    • 研究机关
    • 製药公司

第9章 前临床成像的全球市场:各流通管道

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • 线上
    • 离线

第10章 前临床成像的全球市场:各地区

  • 主要洞察
  • 市场规模及预测，2020年～2033年
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲(MEA)
    • 南美

第11章 北美的前临床成像市场分析

第12章 欧洲的前临床成像市场分析

第13章 亚太地区的前临床成像市场分析

第14章 中东·非洲的前临床成像市场分析

第15章 南美的前临床成像市场分析

第16章 企业简介

  • Agilent Technologies
  • Bruker Corporation
  • Canon
  • Fujifilm Corporation
  • General Electric(GE)
  • Hitachi, Ltd.
  • Hologic
  • Konica Minolta, Inc.
  • Koninklijke Philips
  • Mediso Limited
  • MILabs B.V.
  • Molecubes
  • MR Solutions
  • PerkinElmer, Incorporated
  • Siemens Healthineers
  • TriFoil Imaging
  • Varex Imaging
  • Other Prominent Players
简介目录
Product Code: AA10251531

The preclinical imaging market is experiencing strong and sustained growth, with its value reaching approximately US$ 2,040.6 million in 2024. This upward trajectory is expected to continue, with projections indicating that the market will attain a valuation of around US$ 3,332.2 million by 2033. This represents a compound annual growth rate (CAGR) of 5.6% over the period from 2024 to 2032. Such growth reflects the increasing importance of preclinical imaging in the drug development process and biomedical research.

Several factors are driving this expansion. One of the primary contributors is the growing investment in drug development, as pharmaceutical and biotechnology companies seek to accelerate the discovery and approval of new therapeutics. Alongside this, there is a rising demand for innovative treatments to address unmet medical needs, which further fuels the need for sophisticated preclinical imaging tools. Another significant factor is the growing emphasis on non-invasive imaging techniques. These methods help reduce the reliance on animal models, minimizing ethical concerns and lowering research costs, which is increasingly important in modern biomedical research.

Noteworthy Market Developments

The preclinical imaging market is characterized by intense competition and robust growth, fueled by increasing investments in drug development and biomedical research. Leading companies such as Bruker, Siemens Healthineers, and PerkinElmer are at the forefront of innovation, leveraging strategic partnerships and integrating artificial intelligence (AI) to advance their imaging technologies. These major players are continuously developing sophisticated systems across various modalities, including MRI, PET, CT, and optical imaging, to meet the evolving needs of researchers. A notable example of such innovation occurred in September 2025, when Revvity, Inc. introduced its Living Image(TM) Synergy AI multimodal analysis software designed specifically for in vivo imaging researchers.

Global expansion remains a critical strategic focus within the preclinical imaging market, with the Asia-Pacific region emerging as a vital hub for research and development activities. In 2024, the significance of this region was underscored when eight major international pharmaceutical corporations established new R&D facilities in Beijing, reflecting the growing importance of Asia in the global pharmaceutical and biotechnology landscape. Alongside established companies expanding their presence, the market is also witnessing the entrance of new players. For instance, Verisix, a preclinical imaging contract research organization (CRO), was launched in Paris in 2024 with two initial research platforms.

Core Growth Drivers

The fundamental demand for preclinical imaging is driving a substantial expansion in research pipelines, which in turn is resulting in record-high volumes of studies being conducted. This growth reflects the increasing reliance on advanced imaging techniques to support the development of innovative therapies. For example, in 2024, the number of active preclinical programs focused on complex cell and gene therapies that require in vivo tracking exceeded 800. These programs highlight the critical role of imaging in monitoring the behavior and efficacy of cutting-edge treatments within living organisms.

Emerging Opportunity Trends

A powerful new opportunity in the preclinical imaging field is emerging with the adoption of clearing-enhanced fluorescence tomography (CFT). This innovative imaging modality uniquely bridges the gap between whole-animal optical imaging and high-resolution ex vivo microscopy, offering researchers the ability to visualize biological processes in unprecedented detail. In 2024, at least five major pharmaceutical companies incorporated CFT platforms into their drug discovery workflows, particularly to enhance biodistribution studies for complex biologics. By enabling precise three-dimensional localization of signals with resolutions as fine as 4 microns, CFT delivers an imaging capability that is an order of magnitude more detailed than traditional optical methods.

Barriers to Optimization

The lack of standardized imaging protocols across various research sites and studies presents a significant challenge that could impede the growth of the preclinical imaging market. Variability in imaging techniques, equipment settings, and data interpretation methods can lead to inconsistencies in research outcomes, making it difficult to compare or reproduce results across different laboratories. This inconsistency undermines the reliability and credibility of preclinical imaging data, which is critical for advancing drug development and scientific discovery.

Detailed Market Segmentation

By Type, the products segment continues to dominate the preclinical imaging market, holding a commanding share of 67.8%. This strong leadership position is largely driven by the ongoing development and introduction of innovative imaging systems and reagents that cater to the evolving needs of researchers. Companies operating in this space are consistently expanding their product portfolios, ensuring that they offer the latest technological advancements and a diverse range of solutions to meet increasing demand.

By Product, ultrasound imaging has firmly established itself as the leading product in the preclinical imaging market, securing a significant market share exceeding 25%. Its widespread adoption is largely attributable to its unique ability to provide real-time imaging, a feature that is indispensable in many preclinical research applications. This real-time capability allows researchers to observe biological processes as they happen, providing immediate feedback and detailed insights that static imaging techniques cannot offer.

By Application, the research and development (R&D) segment holds a commanding share of 58.9% of the revenue in the preclinical imaging market, underscoring the critical role that preclinical imaging plays in the study of complex diseases. This substantial share reflects the intense focus and investment in understanding the underlying mechanisms of various illnesses, which drives the demand for precise and advanced imaging technologies. Preclinical imaging has become an indispensable tool in modern drug discovery, offering researchers the ability to visualize disease progression in real time and evaluate the effectiveness of potential treatments at early stages.

By End Users, biotechnology companies have become the foremost end-users in the preclinical imaging market, commanding a significant 45.3% share of the total revenue. Their dominant position is largely attributed to the rapid expansion of the biotech sector, particularly in regions like North America and Asia-Pacific. This growth is fueled by increased investments, scientific advancements, and a surge in the development of innovative therapies, all of which drive a substantial need for advanced imaging technologies. These technologies are crucial for the detailed and precise evaluation of biological processes in the early stages of drug development.

Segment Breakdown

By Type

  • Products
  • Instruments
  • Reagents
  • Software Tools
  • Imaging Services

By Product

  • CT Imaging
  • Optical Imaging
  • Ultrasound Imaging
  • MRI Imaging
  • PET/SPECT Imaging
  • Others

By Application

  • Research and Development
  • Drug Discovery

By End User

  • Biotech Companies
  • Research Institutes
  • Pharmaceutical Companies

By Distribution Channel

  • Online
  • Offline

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding lead in the global preclinical imaging market, capturing a substantial 43.2% share. This dominant position results from a powerful combination of factors, including strong government funding, active venture capital investments, and extensive pharmaceutical research activities concentrated in the region. The U.S. National Institutes of Health (NIH) plays a pivotal role in this growth by awarding over 150 new grants in 2024 specifically for projects that require advanced in vivo imaging techniques. These grants significantly enhance research capabilities and drive innovation in preclinical imaging technologies.
  • In Canada, government support has also contributed to the region's prominence. The Canadian Foundation for Innovation (CFI) program made a major investment in 2024 by funding the acquisition of eight new high-field MRI systems at university research centers. This infrastructure upgrade strengthens the research ecosystem, enabling more sophisticated imaging studies and fostering scientific advancements in preclinical research. Complementing these developments, the U.S. Food and Drug Administration's (FDA) Animal Model Qualification Program approved three new imaging-based biomarkers for use in preclinical trials during 2024.

Leading Market Participants

  • Agilent Technologies
  • Bruker Corporation
  • Canon
  • Fujifilm Corporation
  • General Electric (GE)
  • Hitachi
  • Hologic
  • Konica Minolta, Inc.
  • Koninklijke Philips
  • Mediso Limited
  • MILabs B.V.
  • Molecubes
  • MR Solutions
  • PerkinElmer, Incorporated
  • Siemens Healthineers
  • TriFoil Imaging
  • Varex Imaging
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Preclinical Imaging Market

Chapter 4. Global Preclinical Imaging Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributer
    • 4.1.4. End User
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunity
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Preclinical Imaging Market, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Products
      • 5.2.1.1. Instruments
      • 5.2.1.2. Reagents
      • 5.2.1.3. Software Tools
    • 5.2.2. Imaging Services

Chapter 6. Global Preclinical Imaging Market, By Product

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. CT Imaging
    • 6.2.2. Optical Imaging
    • 6.2.3. Ultrasound Imaging
    • 6.2.4. MRI Imaging
    • 6.2.5. PET/SPECT Imaging
    • 6.2.6. Others

Chapter 7. Global Preclinical Imaging Market, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Research and Development
    • 7.2.2. Drug Discovery

Chapter 8. Global Preclinical Imaging Market, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Biotech Companies
    • 8.2.2. Research Institutes
    • 8.2.3. Pharmaceutical Companies

Chapter 9. Global Preclinical Imaging Market, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. Online
    • 9.2.2. Offline

Chapter 10. Global Preclinical Imaging Market, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. Australia & New Zealand
      • 10.2.3.5. ASEAN
      • 10.2.3.6. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa (MEA)
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Brazil
      • 10.2.5.2. Argentina
      • 10.2.5.3. Rest of South America

Chapter 11. North America Preclinical Imaging Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Preclinical Imaging Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Product
    • 12.2.3. By Application
    • 12.2.4. By End User
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Preclinical Imaging Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Product
    • 13.2.3. By Application
    • 13.2.4. By End User
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Preclinical Imaging Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Product
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Preclinical Imaging Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 15.2.1. By Type
    • 15.2.2. By Product
    • 15.2.3. By Application
    • 15.2.4. By End User
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Sales Composition Ratio, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Agilent Technologies
  • 16.2. Bruker Corporation
  • 16.3. Canon
  • 16.4. Fujifilm Corporation
  • 16.5. General Electric (GE)
  • 16.6. Hitachi, Ltd.
  • 16.7. Hologic
  • 16.8. Konica Minolta, Inc.
  • 16.9. Koninklijke Philips
  • 16.10. Mediso Limited
  • 16.11. MILabs B.V.
  • 16.12. Molecubes
  • 16.13. MR Solutions
  • 16.14. PerkinElmer, Incorporated
  • 16.15. Siemens Healthineers
  • 16.16. TriFoil Imaging
  • 16.17. Varex Imaging
  • 16.18. Other Prominent Players